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OBJECTIVES: Evidence concerning medical-care costs among
advanced-staged NSCLC patients is lacking. The purpose of this
analysis was to identify costs associated with ﬁrst-line
chemotherapy treatment and total lifetime medical-care costs
among elderly Stage IIIB/IV NSCLC patients treated with com-
monly used two-drug chemotherapy (“doublet”) regimens.
METHODS: Study patients included those aged 65 years and
older who were diagnosed with Stage IIIB/IV NSCLC in a SEER
cancer registry between 1997 and 2002 and who received ﬁrst-
line treatment with a commonly used doublet regimen. Study
patients were followed in the SEER-Medicare database to eval-
uate costs while on ﬁrst-line chemotherapy treatment as well as
lifetime medical-care costs. Pairwise comparisons of costs esti-
mated using non-parametric bootstrap methods were generated.
RESULTS: Lifetime medical-care costs totaled approximately
$70,000 among study patients, with almost half incurred while
on ﬁrst-line treatment. These costs were dominated by hospital-
ization and physician costs. Lifetime costs among patients
treated with cisplatin or carboplatin and taxane (C/CT) were sig-
niﬁcantly higher than those for patients treated with cisplatin 
or carboplatin and gemcitabine (C/CG) (difference: $4781
[$1558–$8039]), and those for patients treated with other
doublet therapy (difference: $5961 [$2333–$9614]). Comparing
costs while on ﬁrst-line therapy, costs among patients treated
with C/CT were signiﬁcantly higher than those among patients
treated with C/CG ($5825 [$3872–$7770]), C/C and other
($5968 [$3995–$7975]), or other doublet therapy ($3663
[$1620–$5740]). CONCLUSION: Lifetime medical-care costs
and costs while on ﬁrst-line chemotherapy among treated Stage
IIIB/IV NSCLC patients are substantial, with the highest costs
among patients treated with doublet platinum and taxane 
regimens.
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OBJECTIVES: SCLC is estimated to represent 10–20% of lung
cancer cases, however, the lack of speciﬁc ICD-9 diagnosis codes
to differentiate SCLC and NSCLC poses challenges in claims
data research. This study aims to (1) develop a deﬁnitional algo-
rithm to identify SCLC in a large claims database, and to (2)
assess payer costs associated with IV chemotherapy in SCLC.
METHODS: Using medical claims data from 5.5 million bene-
ﬁciaries between 01/01/1998 and 01/31/2006, we identiﬁed 8605
patients with lung cancer (ICD-9 codes 162.3–162.9, 176.4, or
197.0) receiving IV chemotherapies. We then identiﬁed SCLC 
by the following chemotherapies principally used for SCLC: 
cisplatin/etoposide, cisplatin/irinotecan, carboplatin/etoposide
(aged 60 and over), or topotecan. We further limited this subset
to exclude patients receiving treatments or procedures often
associated with NSCLC: PET scan imaging, lung removal or
resection surgery, and the regimen of carboplatin/paclitaxel. We
computed average total costs paid per day of IV chemotherapy
as well as the separate costs for IV chemotherapy drugs, IV
chemotherapy administration procedures, and other drugs and
services received on those days. RESULTS: A total of 1254
(14.6%) of patients with lung cancer had received a SCLC
chemotherapy regimen, and the subset decreased to 942 (10.9%)
when applying all exclusion criteria. Among the identiﬁed subset,
average total cost per day was $815, with $423 (52%) attribut-
able to IV chemotherapy drugs, $89 (11%) to IV chemotherapy
administration procedures, and $303 (37%) to other drugs and
services. CONCLUSION: The proposed algorithm identiﬁed
about 11% of all patients with lung cancer as SCLC from claims
data, a proportion comparable to published estimates. IV
chemotherapy administration procedures and other visit-related
drugs and services accounted for 48% of total costs per IV visit
in these patients. The increased availability and use of oral
chemotherapies in SCLC could provide savings to payers by off-
setting some of these costs.
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OBJECTIVES: CML has a worldwide incidence between 1 and
2 per 100,000 and accounts for 15% of all leukemia patients. In
the US, the total 2004 hospitalization costs for CML patients
was estimated at $69 million. However, beyond that ﬁgure, little
information is available on costs of other resources for treating
CML patients or how the costs vary with severity of illness. The
objective was to estimate the costs of treating CML and the unin-
tended effects of treatment according to disease phase, response
type to treatment, and time since diagnosis (0 to 3, 4 to 12 and
>12 months). METHODS: Using a questionnaire based on
current treatment guidelines, we elicited the expert opinion of
ﬁve oncologists and the frequency of resource use in: outpatient
visits, laboratory tests and other interventions. Costs were
obtained from publicly available sources and are presented in
2006 USD. RESULTS: In the ﬁrst three months of each phase, a
patient responding to treatment was estimated to cost: $744
(low: $325, high: $2654) in chronic phase, $983 ($420, $4119)
in accelerated phase, and $5979 ($442, $21,047) in blast phase.
A patient not responding to treatment was estimated to cost
$1002 ($478, $3407) in chronic phase, $1427 ($773, $6617) in
accelerated phase, and $10,496 ($876, $34,471) in blast phase.
Costs were higher for patients not responding to treatment,
increased as patients progressed through the disease phases of
CML and decreased with longer time in the phase. CONCLU-
SION: Higher costs were associated with patients not respond-
ing to treatment in each phase of CML. Although choice of
treatment is determined according to patients’ responses, disease
progression and time since diagnosis, published cost-effective-
ness models do not necessarily incorporate all these parameters.
The estimates collected in the current study will serve as repro-
ducibly measured inputs in future models.
